• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

CVS Isn't Looking All That Healthy But There's a Trade to Be Made

I was trying really hard to like CVS today, but I do not love this balance sheet.
By STEPHEN GUILFOYLE
Feb 08, 2023 | 11:05 AM EST
Stocks quotes in this article: CVS, OSH

Is it time... to get back into CVS Health (CVS) ? The stock closed on Tuesday afternoon down 18% in less than two months, while the equity markets in general, have gone the other way. Before making this decision, there is a lot of wood to cut. CVS Health is in the news on Wednesday morning. In fact, the company is all over the news.

First up, the seemingly months of speculation are over. CVS Health has announced that the firm will acquire Oak Street Health (OSH) for $39 per share, or about $10.6B. This will be an all-cash deal that is expected to close in 2023, subject to the approval of OSH shareholders. Oak Street CEO Mike Pykosz will stay on the job until the transaction is final.

Oak Street operates about 169 health care centers across 21 states in the US and attended to a rough 210K patients over the three month period ended last September. Oak employs 600 or so primary care providers. CVS believes that by 2026, Oak Street will be running over 300 centers and that each center will have the potential to contribute $7M of Oak adjusted EBITDA when at maturity. That would be more than $2B in aggregate.

CVS also projects more than $500M in synergies savings potential over time. The all-cash deal will be funded through available resources and existing financing capacity. The firm is committed to maintaining its current credit rating.

Earnings

On Wednesday morning, CVS Health released the firm's fourth quarter financial results. For the three month period ended December 31st, CVS posted an adjusted EPS of $1.99 (GAAP EPS: $1.75) on revenue of $83.846B. The top line number decisively beat Wall Street with a print that was good for year over year growth of 9.4%.

The bottom line numbers also beat Wall Street, while the adjusted number improved by one penny compared to the year ago period and the GAAP print improved dramatically. The lion's share of the adjustment made for the quarter reported was for the amortization of intangible assets, while for the year ago period, the firm took an impairment amounting to $1.02 per share related to the stores that just is not there this time around.

Segment Performance

- Health Care Benefits (Offers a range of insured and self insured medical, pharmacy, dental, and behavioral health products and services.) generated revenue of $23.033B (+11.3%), producing adjusted operating income of $858M (+68.2%). Total medical membership increased to roughly 24.4M (+109K over three months, +548K over 12 months).

- Pharmacy Services (Provides a range of pharmacy benefit management solutions to employers, health plans, government employee groups, and government sponsored programs.) generated revenue of $43.747B (+11.2%), producing adjusted operating income of $1.988B (+9%). Total pharmacy claims processed increased to $600.4M (+3.1%).

- Retail/LTC (Fulfills prescriptions for medications, provides patient care programs, walk-in clinics, vaccine administration and diagnostic testing, while also selling a wide array of health and wellness products as well as general merchandise.) generated revenue of $28.184B (+4%), producing adjusted operating income of $1.84B (-25.1%). The drop in operating income for this segment was largely due to decreased demand for Covid vaccination and diagnostic testing.

Guidance

For the full year, CVS Health sees GAAP EPS in a range spanning from $7.73 to $7.93. Full year adjusted EPS is expected to land in between $8.70 and $8.90. This does drag the midpoint of expectations below the consensus view of $8.86. CVS also sees full year adjusted cash flow from operations at $12.5B to $13.5B.

Fundies

For the full year 2022, cash flow from operating activities printed at $16.177B, which was down from $18.255B in 2021. Readers can now see that the above guidance for adjusted cash flow is less than impressive. The firm ended the quarter with a net cash position of $15.723B and inventories of $19.09B on the balance sheet.

Both were up moderately over 12 months. This took current assets up to $65.682B. Current liabilities added up to $69.736, leaving the firm with a current ratio of 0.94, which is really a touch lower than we like to see. Sans those inventories, the firm's quick ratio works out to 0.67. That too, is sub-optimal.

Total assets amount to $228.275B, including $102.904B in "goodwill" and other intangibles. At 45% of total assets, I do find that a little bit on the high side. Total liabilities less equity comes to $156.96B. This includes long-term debt of $50.476B that combined with debt labeled as current, brings the debt-load to $52.254B.

As readers could tell, I was trying really hard to like CVS today as that name has done well for me in the past, but I do not love this balance sheet. I don't like the current ratio and I don't like the imbalance between cash on hand and total debt.

This is not an immediate problem, but I can see why the firm is concerned about the acquisition of Oak Street potentially impacting its credit rating if not paid for in cash. Given the operating cash flow, which though in decline is still quite robust, the firm should be able to protect the dividend.

My Thoughts

Readers can see that the shares of CVS have now been in a descending channel for more than a year. Ever so slowly, each high has been lower than the one prior and each low has been lower than the one prior. The channel, however, is about $20 across, so money can certainly be made trading the range regardless of the trajectory of said range.

The stock trades at 10 times next year's earnings, which is not inexpensive. That's the price of having to work within a sloppy looking balance sheet. That said, CVS does pay shareholders $2.42 per year to stick around for a yield of 2.81%. That is attractive.

I could see initiating CVS on a hold of that 21-day EMA (exponential moving average) ($88). The stock does not seem to respect neither its 200-day SMA (simple moving average) nor its 50-day SMA, so that's the line to watch as clearly that line had been resistance since early December.

My thinking is that unless this one is in the portfolio as an income stock that it's a trade, and that trade would have a target of about $102, which is where the upper trendline will come into play.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Mergers and Acquisitions | Earnings | Investing | Stocks | Technical Analysis | Trading | Healthcare

More from Investing

Market's Narrow and Dull but Not Bad

James "Rev Shark" DePorre
Mar 29, 2023 4:26 PM EDT

Here are the two things that stood out in Wednesday's trading.

Battery Maker Enovix Could Soon Be Charged Up to Rally Further

Bruce Kamich
Mar 29, 2023 2:56 PM EDT

The stock has been impressive but gains from here may be harder to achieve.

This Software ETF Could Tell Us Where the Industry Is Headed

Bruce Kamich
Mar 29, 2023 1:54 PM EDT

Let's see the charts of the iShares Expanded Tech-Software Sector exchange-traded fund.

Add This 'Best Idea' to Your Precious Metals Portfolio

Bruce Kamich
Mar 29, 2023 1:21 PM EDT

Shares of this Canada-based company could rise more than 30% from here.

Except for Energy, I'd Be Wary of Cyclical Stocks

Bret Jensen
Mar 29, 2023 11:30 AM EDT

Another increasing concern for equities is that we are likely to see an 'earnings recession'.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login